Viewing nowJW Pioglitazone 15 mg Tablet (Pioglitazone Hydrochloride)
Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
JW Pharmaceutical Co., Ltd.

MFDS item code 202002025 · Approved 2020.03.23
Improvement of glycemic control in type 2 diabetes mellitus
This medicine is used as an adjunct to dietary and exercise therapy to improve blood sugar control in patients with type 2 diabetes. It can be administered as monotherapy and can be combined with sulfonylureas, metformin, or insulin if there is no effect from other oral hypoglycemics. Additionally, nutritional counseling, weight loss, and consistent exercise therapy are important for patients, which are essential not only for initial treatment but also for maintaining the effectiveness of drug therapy. This medicine helps to improve blood sugar control.
This drug is administered orally once daily, regardless of meals. Management of diabetes should be individualized. Ideally, response to treatment should be assessed by monitoring glycated hemoglobin (HbA1c), which is a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the previous 2 ~ 3 months. Clinically, this drug should be administered to patients with diabetes for an adequate period (at least 3 months) to assess changes in glycated hemoglobin, provided that their blood glucose control does not worsen. 1. Monotherapy This drug may be initiated as monotherapy at 15 mg once daily of pioglitazone in patients whose blood glucose is not adequately controlled by diet and exercise. If an adequate effect is not achieved with the initial dose, this drug may be increased to 30 mg once daily. Combination therapy should be considered in patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This drug may be administered in combination with a sulfonylurea, with an initial dose of 15 mg once daily. When used in combination with this drug, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This drug may be administered in combination with metformin, with an initial dose of 15 mg once daily. When used in combination with this drug, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this drug. 3) Insulin: This drug may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be continued when combination therapy with this drug is initiated. However, if a patient receiving this drug in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Precautions, Patients with Renal Impairment). Treatment with this drug should not be initiated if, at the start of therapy, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (at least 2.5 times the upper limit of normal for ALT) (see Adverse Reactions and Precautions, Effects on the Liver). Monitoring of liver enzymes is recommended in all patients before starting treatment with this drug and periodically thereafter. There are no data on the use of this drug in combination therapy with other thiazolidinediones.
Administration is not recommended in children under 18 years of age because there is no experience with its use.
This medicine is used for the treatment of type 2 diabetes and helps regulate blood sugar by improving insulin resistance. This medicine may worsen or induce a condition called congestive heart failure, so it should not be administered to patients with heart failure or a history of heart failure. During treatment, symptoms such as weight gain, edema, and dyspnea may occur, and if these symptoms arise, healthcare professionals should be informed immediately. Patients with active bladder cancer or a history of bladder cancer should not use this medicine, and if hematuria or urinary disturbances develop or worsen, the possibility of bladder cancer should be considered and the physician should be notified. Patients with impaired liver function should also use this medicine cautiously and undergo regular liver function tests before and during treatment. The risk of hypoglycemia may increase when this medicine is used in conjunction with insulin, so patients should be well-informed about the symptoms of hypoglycemia and how to respond, and insulin dosage adjustments may be necessary if needed. This medicine can cause edema and weight gain, so patients with existing edema or at risk of heart disease should exercise extra caution. Pre-menopausal women may experience enhanced ovulation leading to increased chances of pregnancy when using this medicine, thus appropriate contraceptive methods should be employed. Elderly patients or those with impaired kidney and liver function may have a higher risk of side effects when taking this medicine, so it should be used carefully under the guidance of healthcare professionals. It is advisable for women who are pregnant or may become pregnant to avoid using this medicine, and those who are breastfeeding should consult their physician before use. This medicine may interact with other medications, so patients must inform their healthcare provider about any other medications they are taking. Regular blood glucose and liver function tests should be conducted during treatment, and patients should closely observe any changes in weight, edema, or dyspnea. It is important to consult a physician immediately if any unusual symptoms arise during medication use to receive appropriate care.
Congestive heart failure, excessive and rapid weight change, dyspnea, edema, fluid retention, inadequate blood glucose control, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, low back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular factors, hospitalization due to worsening of congestive heart failure, emergency room visit due to congestive heart failure, edema, liver failure, decreased vision, diabetic macular edema, hepatotoxicity, elevated serum ALT levels, elevated serum bilirubin levels, decreased hemoglobin, decreased hematocrit, isolated elevated serum creatine kinase, bladder cancer, dizziness, loss of appetite, constipation, upper abdominal pain, chest pain, fatigue, weakness, dyspepsia, nausea, dyspnea, itching, chest discomfort, tremors, chills, gastrointestinal disease, abdominal pain, epigastric discomfort, numbness, muscle stiffness, discomfort in the head, worsening liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, heart failure.
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a container that can block light and air, and should be kept away from humid areas. The storage temperature should be between 15 degrees to 30 degrees, ideally around 25 degrees.
This medicine is a white round tablet.
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
JW Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kyungdong Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.